Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab acquired 212,177 shares of Merus stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $97.00 per share, with a total value of $20,581,169.00. Following the transaction, the insider owned 71,946,801 shares in the company, valued at approximately $6,978,839,697. This represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

A/S Genmab also recently made the following trade(s):

• On Friday, December 19th, A/S Genmab bought 66,264 shares of Merus stock. The stock was acquired at an average price of $97.00 per share, for a total transaction of $6,427,608.00.
• On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The shares were acquired at an average cost of $97.00 per share, with a total value of $14,627,115.00.
• On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, with a total value of $11,712,944.00.

Merus Stock Down 0.1%

Merus stock traded down $0.06 during mid-day trading on Monday, hitting $96.95. The company's stock had a trading volume of 501,154 shares, compared to its average volume of 1,271,123. The stock has a market capitalization of $7.35 billion, a P/E ratio of -18.29 and a beta of 1.06. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $97.14. The stock's fifty day moving average price is $95.66 and its two-hundred day moving average price is $76.05.

Analysts Set New Price Targets

A number of brokerages have weighed in on MRUS. Lifesci Capital reaffirmed a "market perform" rating and issued a $97.00 price target on shares of Merus in a research report on Tuesday, September 30th. Barclays reiterated an "equal weight" rating and issued a $97.00 price objective (down previously from $112.00) on shares of Merus in a research report on Tuesday, September 30th. Leerink Partnrs downgraded shares of Merus from a "strong-buy" rating to a "hold" rating in a research report on Sunday, October 5th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a research note on Monday, August 25th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Merus in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merus currently has an average rating of "Hold" and an average price target of $93.56.

Check Out Our Latest Analysis on MRUS

Institutional Trading of Merus

Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its position in Merus by 12.3% during the 3rd quarter. Avoro Capital Advisors LLC now owns 3,542,500 shares of the biotechnology company's stock worth $333,526,000 after acquiring an additional 386,945 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Merus by 18.8% in the second quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company's stock valued at $117,048,000 after buying an additional 351,616 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Merus by 4.4% in the third quarter. Westfield Capital Management Co. LP now owns 2,132,489 shares of the biotechnology company's stock valued at $200,774,000 after purchasing an additional 90,101 shares during the last quarter. Finally, Woodline Partners LP grew its stake in Merus by 8.5% in the 3rd quarter. Woodline Partners LP now owns 1,674,167 shares of the biotechnology company's stock valued at $157,623,000 after purchasing an additional 131,267 shares during the period. Institutional investors own 96.14% of the company's stock.

About Merus

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.

Further Reading

• Five stocks we like better than Merus
• Wall Street Stock picker Names #1 Stock of 2026
• Do not delete, read immediately
• How Long Will $1M Last in Retirement?
• Nvidia CEO Issues Bold Tesla Call
• GOLD ALERT

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merus Right Now?

Before you consider Merus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.

While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here